Prescription weight-management treatment depends on the medication, your health history, the prescriber’s assessment, and the rules that apply where care is delivered. Meeting a BMI threshold does not guarantee a prescription or insurance coverage.
JourneyLite visits and prescription follow-up
JourneyLite’s medication follow-up schedule is a visit every four weeks, with an in-person visit at least every three months, including the initial visit. Your care team will confirm which visits can be virtual and whether your treatment requires closer monitoring.
If an appointment is overdue or treatment has been interrupted, contact the team before restarting medication. Refills and a safe restart plan require provider review; do not assume that a missed visit creates the same medication-free interval for every drug or state.
Ohio: controlled medications for obesity
Ohio’s current rule took effect February 28, 2023. For initiation, it generally requires BMI 30 or above, or at least 27 with a qualifying condition. Continuing treatment requires at least 5% loss of initial weight during the first three months, appropriate benefit, and tolerability. Continuing a medication labeled for short-term use beyond three months requires maintaining that 5% reduction and documented follow-up at least every three months, including weight, blood pressure, and heart rate. Other assessment and monitoring requirements also apply.
See Ohio Administrative Code 4731-11-04. This rule does not impose a universal three-month maximum or an automatic three-month break after every interruption.
Kentucky: controlled appetite suppressants
Kentucky’s physician and physician-assistant rule lists BMI 27 or above, or BMI 25–27 with specified medical risk factors, among several possible assessment criteria. It also requires a documented evaluation, a treatment plan, monitoring, and prescription-history review. Use beyond three months must be justified in the medical record; the rule does not establish a blanket twelve-month treatment limit or a mandatory six-month break for every patient.
These state criteria do not change a medication’s FDA labeling or establish that it is suitable for you. See Kentucky 201 KAR 9:016. Requirements can differ by prescriber license and location.
Medication labeling and state rules are different
Adipex-P (phentermine) is FDA-labeled for short-term use of a few weeks. Longer use is off-label, even where state rules permit it, and requires an individualized discussion of benefits, risks, alternatives, and monitoring. See the Adipex-P prescribing information.
Medications approved for long-term weight management have their own eligibility, safety, dosing, and response criteria. Qsymia contains phentermine and is controlled; Contrave and GLP-1 medications are different treatments. They do not share one universal refill schedule or stopping rule. Your provider will use the relevant prescribing information and your response to treatment.
Prepare for your next visit
Bring an up-to-date medication list and discuss side effects, progress, costs, pregnancy plans when relevant, and any interruption in treatment. Your provider can explain whether to continue, change, or stop a medication. Do not combine weight-loss drugs or change your dose without that guidance.
Explore medical weight loss options, medication costs and coverage, or request a consultation.